Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Petrie

Showing results (271-280 of 557) with videos related to

Pageof 56
Sort By:
JACC. Heart Failure|June 2, 2018
Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial: Percutaneous Coronary Intervention for Ischemic CardiomyopathyDivaka Perera, Tim Clayton, Mark C Petrie, et al.
BMJ (Clinical Research Ed.)|September 29, 2001
Randomised controlled trial of specialist nurse intervention in heart failureL Blue, E Lang, J J McMurray, et al.
Circulation. Heart Failure|October 8, 2009
Discordant short- and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex: a population study of 5.1 million people in ScotlandMichael R MacDonald, Pardeep S Jhund, Mark C Petrie, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 18, 2020
Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysisMatthew M Y Lee, Kieran F Docherty, Naveed Sattar, et al.
Nature Cardiovascular Research|June 13, 2025
Secondary analysis of the EMPACT-MI trial reveals cardiovascular-kidney efficacy and safety of empagliflozin after acute myocardial infarctionRahul Aggarwal, Deepak L Bhatt, Adrian F Hernandez, et al.
European Journal of Heart Failure|April 27, 2016
The incremental prognostic and clinical value of multiple novel biomarkers in heart failureColette E Jackson, Caroline Haig, Paul Welsh, et al.
Circulation. Cardiovascular Interventions|November 12, 2016
Discordance Between Resting and Hyperemic Indices of Coronary Stenosis Severity: The VERIFY 2 Study (A Comparative Study of Resting Coronary Pressure Gradient, Instantaneous Wave-Free Ratio and Fractional Flow Reserve in an Unselected Population Referred for Invasive Angiography)Barry Hennigan, Keith G Oldroyd, Colin Berry, et al.
Journal of the American Heart Association|November 7, 2012
Microvascular Resistance Predicts Myocardial Salvage and Infarct Characteristics in ST-Elevation Myocardial InfarctionAlexander R Payne, Colin Berry, Orla Doolin, et al.
European Journal of Heart Failure|October 23, 2010
The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarctionAmil M Shah, Hajime Uno, Lars Køber, et al.
Journal of the American College of Cardiology|July 16, 2013
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity)Chih M Wong, Nathaniel M Hawkins, Pardeep S Jhund, et al.
Pageof 56

Showing results (271-280 of 557) with videos related to

Sort By:
Pageof 56
JACC. Heart Failure|June 2, 2018
Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial: Percutaneous Coronary Intervention for Ischemic CardiomyopathyDivaka Perera, Tim Clayton, Mark C Petrie, et al.
BMJ (Clinical Research Ed.)|September 29, 2001
Randomised controlled trial of specialist nurse intervention in heart failureL Blue, E Lang, J J McMurray, et al.
Circulation. Heart Failure|October 8, 2009
Discordant short- and long-term outcomes associated with diabetes in patients with heart failure: importance of age and sex: a population study of 5.1 million people in ScotlandMichael R MacDonald, Pardeep S Jhund, Mark C Petrie, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 18, 2020
Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysisMatthew M Y Lee, Kieran F Docherty, Naveed Sattar, et al.
Nature Cardiovascular Research|June 13, 2025
Secondary analysis of the EMPACT-MI trial reveals cardiovascular-kidney efficacy and safety of empagliflozin after acute myocardial infarctionRahul Aggarwal, Deepak L Bhatt, Adrian F Hernandez, et al.
European Journal of Heart Failure|April 27, 2016
The incremental prognostic and clinical value of multiple novel biomarkers in heart failureColette E Jackson, Caroline Haig, Paul Welsh, et al.
Circulation. Cardiovascular Interventions|November 12, 2016
Discordance Between Resting and Hyperemic Indices of Coronary Stenosis Severity: The VERIFY 2 Study (A Comparative Study of Resting Coronary Pressure Gradient, Instantaneous Wave-Free Ratio and Fractional Flow Reserve in an Unselected Population Referred for Invasive Angiography)Barry Hennigan, Keith G Oldroyd, Colin Berry, et al.
Journal of the American Heart Association|November 7, 2012
Microvascular Resistance Predicts Myocardial Salvage and Infarct Characteristics in ST-Elevation Myocardial InfarctionAlexander R Payne, Colin Berry, Orla Doolin, et al.
European Journal of Heart Failure|October 23, 2010
The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarctionAmil M Shah, Hajime Uno, Lars Køber, et al.
Journal of the American College of Cardiology|July 16, 2013
Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity)Chih M Wong, Nathaniel M Hawkins, Pardeep S Jhund, et al.
Pageof 56